CUSIP No. 3621LQ109
Page 15 of 20
G1 Therapeutics, Inc. (the “Issuer”)
Item 1(b) | Address of Issuer’s Principal Executive Offices |
700 Park Office Drive, Suite 200, Research Triangle Park, North Carolina 27709.
Item 2(a) | Name of Person Filing |
This Amendment No. 2 to Schedule 13G is being filed by:
Hatteras Venture Partners IV SBIC, L.P. (“HVP SBIC”)
Hatteras Venture Advisors IV SBIC, LLC (“HVA SBIC”)
Hatteras NC Fund, L.P. (“Hatteras Fund”)
Hatteras Venture Advisors IV, LLC (“HVA IV”)
Hatteras Venture Partners IV, L.P. (“HVP IV”)
Hatteras Venture Advisors V, LLC (“HVA V”)
Hatteras Venture Partners V, L.P. (“HVP V”)
John C. Crumpler
Clay B. Thorp
Christy Shaffer
Kenneth B. Lee
Douglas Reed
Robert A. Ingram
(collectively, the “Reporting Persons”).
Item 2(b) | Address of Principal Business Office, or if none, Residence |
280 S. Mangum Street, Suite 350, Durham, North Carolina 27701.
The Reporting Persons are citizens of:
HVP SBIC — Delaware
HVA SBIC — Delaware
Hatteras Fund — Delaware
HVA IV —North Carolina
HVP IV — Delaware
HVA V — North Carolina
HVP V — Delaware
John C. Crumpler — USA
Clay B. Thorp — USA
Christy Shaffer — USA
Kenneth B. Lee — USA
Douglas Reed — USA
Robert A. Ingram — USA